0
Orphan Designations
1
FDA Approvals
Latest: BEYFORTUS (2023)
26
Active Trials
200 recruiting
12
Rare Diseases
across 28 areas
8
News (30d)
Trending
Sanofi Pasteur Inc. is a company with 0 orphan drug designations across 12 rare diseases, including 1 FDA-approved therapy. Active clinical trials in 26 indications. gene therapy candidates in 1 disease. 27 active policy bills affect their portfolio. 8 news articles in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| celiac disease | - | Des.TrialAppr. |
| chronic inflammatory demyelinating polyradiculoneuropathy | - | Des.TrialAppr. |
| cystic fibrosis | - | Des.TrialAppr. |
| diabetes mellitus | - | Des.TrialAppr. |
| epilepsy | - | Des.TrialAppr. |
| hemophilia A | - | Des.TrialAppr. |
| hemophilia B | - | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| multiple sclerosis | - | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
| sickle cell disease | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
95
overlap in 2+ diseases
1/12
candidate diseases
8
avg importance: 63
27
affecting portfolio
0% of portfolio targets high unmet need diseases
95
overlap in 2+ diseases
1/12
candidate diseases
8
avg importance: 63
27
affecting portfolio